Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 5/20 | 0.49 |
| ▸ | KDR | P35968 | 13/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5079432 | 0.91 | CHEK1 (0.49) | CHEK1KDR | |
| SCHEMBL5078737 | 0.82 | CHEK1 (0.52) | CHEK1KDR | |
| SCHEMBL5076160 | 0.81 | CHEK1 (0.59) | CHEK1KDR | |
| SCHEMBL14559471 | 0.81 | CHEK1 (0.55) | CHEK1KDR | |
| SCHEMBL145148 | 0.81 | CHEK1 (0.55) | CHEK1KDR | |
| SCHEMBL5078741 | 0.79 | CHEK1 (0.52) | CHEK1KDR | |
| SCHEMBL175100 | 0.79 | CHEK1 (0.53) | CHEK1KDR | |
| SCHEMBL146970 | 0.76 | KDR (0.66) | CHEK1KDR | |
| SCHEMBL14012853 | 0.75 | CHEK1 (0.53) | CHEK1KDR | |
| SCHEMBL5081983 | 0.75 | CHEK1 (0.53) | CHEK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080274107-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-11-06 | — | — | US | disclosed |
| US-20080274107-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-11-06 | — | — | US | disclosed |
| US-20080274107-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-11-06 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274107-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | CHEK1 499/4885KDR 5/4885CTSD 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.